IDH1 and cholangiocarcinoma: Given their prevalence and the fact that there is a targeted therapeutic option for them, several clinical trials have been conducted in recent years to verify their effectiveness [20]. Ivosidenib and olutasidenib are the most widely used and known IDH1 inhibitors, ivosidenib being the first studied in cholangiocarcinoma in a phase 1 study, with encouraging results [21]. Subsequently, the ClarIDHy phase III study enrolled 187 patients with advanced cholangiocarcinoma with IDH1 mutation, who progressed after one or two treatment regimens.